Study | Exclusion reasons | Rmk | Reference |
---|---|---|---|
Elkjaer (Carbamazepine), 2018 | Overlapping: this publication totally included the data of Elkjaer, 2018, for an higher academic grade => use of Ren 2023. |
Elkjaer JAMA Neurol 2018; 75:663-671 10.1001/jamaneurol.2017.5035 |
|
He (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2017 | repeat population groups, duplicate reports (most recent study included) | Patients who developed epilepsy during pregnancy or after delivery were not included. Overlapping: He 2017 totally included in Li 2023, with a longer study period and more pregnancies => Use of Li 2023. |
He Epilepsy Behav 2017; 74:10-14 10.1016/j.yebeh.2017.05.034 |
He (Carbamazepine) (Controls unexposed, sick), 2017 | repeat population groups, duplicate reports (most recent study included) | Patients who developed epilepsy during pregnancy or after delivery were not included. Overlapping: He 2017 totally included in Li 2023, with a longer study period and more pregnancies => Use of Li 2023. |
He Epilepsy Behav 2017; 74:10-14 10.1016/j.yebeh.2017.05.034 |
Gopinath (Carbamazepine), 2015 | repeat population groups, duplicate reports (most recent study included) | Overlapping: Thomas 2022 included data on language and cognitive delay, also evaluated in Sreedharan et al., 2018; Thomas 2007 and Gopinath 2015, but with more exposed pregnancies, more relevant control group and older children => Use of Thomas 2022. |
Gopinath Epilepsy Res 2015; 117:58-62 10.1016/j.eplepsyres.2015.09.003 |
Thomas (Carbamazepine), 2007 | repeat population groups, duplicate reports (most recent study included) | Overlapping: Thomas 2022 included data on language and cognitive delay, also evaluated in Sreedharan et al., 2018; Thomas 2007 and Gopinath 2015, but with more exposed pregnancies, more relevant control group and older children => Use of Thomas 2022. |
Thomas Epilepsia 2007; 48:2234-40 10.1111/j.1528-1167.2007.01376.x |